South African researches from the Wits Reproductive Health and HIV Institute have announced that they have come up with a new preventative measure of HIV, that’s 90-percent effective.
According to a report by local media eNCA, initial results from clinical trials show that taking an injection of PrEP and CAB LA, once every eight weeks, is more effective than taking a daily pill to prevent HIV among women.
According to the researchers however this treatment needs to be accessible to people who might not be able to afford it.
“The company that makes cabotegravir has not allocated a cost yet. But what they have articulated is the importance of access, particularly in low- and middle-income countries in the region where HIV is more prevalent,” said Sinead Delany-Moretlwe.
However, researchers, are also warning that making the drug available should not be rushed.
“We are not looking at something that is going to be available immediately but this is going to be fast track, both from the clinical research point of view and the manufacturing side,” said Helen Rees from the Wits Reproductive Health and HIV Institute.